Sanofi SA (SAN.PA) — Quality & forensics

As of 2026-09-18 — refreshed nightly. Closelook readings from an investment research diary, not ratings or advice.

The Closelook module scores

58 /100 composite · 7 modules · general weight set

Valuation 64
Quality 69
Growth 42
Balance sheet 51
Cash quality 49
Capital allocation 90
Momentum 43

Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.

Financial forensics — the academic screens

2.35 Altman Z-Score

Sits in the grey zone (1.81–2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.

7/9 Piotroski F-Score

Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.

-2.59 Beneish M-Score

Screens reported earnings for statistical manipulation patterns — below the −1.78 manipulation-risk threshold. A screen, not an accusation.

Continue: the SAN.PA chart & overview

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Sanofi SA's Closelook quality reading?

The composite reads 58/100 across 7 modules, as of 2026-09-18: valuation 64, quality 69, growth 42, balance sheet 51, cash quality 49, capital allocation 90, momentum 43. Closelook scores are research diary readings, not ratings or investment advice.

What is Sanofi SA's Altman Z-Score?

2.35, which sits in the grey zone (1.81–2.99) as of 2026-09-18. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.

What is Sanofi SA's Piotroski F-Score?

7 of 9, as of 2026-09-18. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.

What does Sanofi SA's Beneish M-Score indicate?

-2.59 — below the −1.78 manipulation-risk threshold, as of 2026-09-18. The M-Score screens reported earnings for statistical manipulation patterns; it is a screen, not an accusation.

Related in the Closelook universe

same Closelook index seat first, then Drug Manufacturers - General. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.